Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

199
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
199
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

4.8K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.8K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

152
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
152
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Library Docking for Cannabinoid-2 Receptor Ligands.

Journal of medicinal chemistry·2026
Same author

Bioanalysis of Ametryn by UHPLC-MS<sup>3</sup> Coupled With Multiple Fragmentation to Decrease Interference and Enhance Sensitivity.

Rapid communications in mass spectrometry : RCM·2026
Same author

Friend or Foe? The Dual Role of Ferroptosis in Tumor Immunity and Immunotherapy.

WIREs mechanisms of disease·2026
Same author

First Structure-Activity-Relationship Study of Potent G2A Antagonists.

Journal of medicinal chemistry·2026
Same author

Toward a Random Background for Ligand Optimization.

bioRxiv : the preprint server for biology·2026
Same author

The Selectivity Implications of Docking Libraries with Greater and Lesser Similarities to Bio-like Molecules.

Journal of medicinal chemistry·2026
Same journal

Large-scale discovery and annotation of substructure patterns in mass spectrometry profiles.

Nature communications·2026
Same journal

Salmonella SopB suppresses post-transcriptionally regulated cytokine release to reduce early tissue inflammation and delay disease progression.

Nature communications·2026
Same journal

A human-specific microRNA controls the timing of excitatory synaptogenesis.

Nature communications·2026
Same journal

An HMA-like integrated domain in the wheat tandem kinase WTK4 recognises an RNase-like pathogen effector.

Nature communications·2026
Same journal

Learning regularities in noise engages both neural predictive activity and representational changes.

Nature communications·2026
Same journal

The H3K4 methyltransferase KMT2D is an essential cofactor for GATA1 at erythroid gene enhancers.

Nature communications·2026
See all related articles

Related Experiment Video

Updated: May 24, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.5K

Virtual library docking for cannabinoid-1 receptor agonists with reduced side effects.

Tia A Tummino1,2, Christos Iliopoulos-Tsoutsouvas3, Joao M Braz4

  • 1Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, 94158, USA.

Nature Communications
|March 5, 2025
PubMed
Summary
This summary is machine-generated.

Researchers discovered novel cannabinoid chemotypes that act as agonists for the cannabinoid-1 receptor (CB1R). These compounds show potential for pain relief, separating analgesic effects from common cannabinoid side effects.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K
Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

8.7K

Related Experiment Videos

Last Updated: May 24, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.5K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K
Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

8.7K

Area of Science:

  • Medicinal Chemistry
  • Neuroscience
  • Pharmacology

Background:

  • Cannabinoid-1 receptor (CB1R) agonists are pursued for therapeutic applications, particularly pain management.
  • Identifying novel chemotypes with improved side-effect profiles remains a challenge.

Purpose of the Study:

  • To discover novel cannabinoid-1 receptor (CB1R) agonists using virtual screening and structure-based drug design.
  • To develop potent and selective CB1R agonists with a favorable therapeutic window.

Main Methods:

  • Virtual screening of 74 million molecules against the CB1R target.
  • De novo synthesis and radioligand competition assays for hit prioritization.
  • Structure-based optimization and cryo-electron microscopy (cryo-EM) for structural elucidation.
  • In vivo analgesic testing in male mice, assessing therapeutic window and side effects.

Main Results:

  • Identified nine active CB1R agonists from 46 synthesized compounds, achieving a 20% hit rate.
  • Optimized a lead compound to '1350, a potent 0.95 nM full agonist of CB1R.
  • Cryo-EM structure confirmed the docked pose of '1350 in complex with CB1R-Gi1.
  • Compound '1350 demonstrated strong analgesia in male mice with a significant therapeutic window over adverse effects like hypolocomotion, sedation, and catalepsy.
  • No conditioned place preference was observed with '1350, suggesting a dissociation of analgesic effects from rewarding properties.

Conclusions:

  • Novel cannabinoid chemotypes can be effectively identified through virtual screening and structure-based design.
  • The developed CB1R agonist '1350 exhibits potent analgesic activity with a promising safety profile.
  • These findings support the potential of unique cannabinoid chemotypes to disentangle pain relief from undesirable side effects, paving the way for new pain therapeutics.